Table 1.
Updated phase III clinical trials investigating immunotherapies for advanced ccRCC.
| Study Name | Identifier | Agent | Target | Total | ORR | TRAE 3+ | Citations |
|---|---|---|---|---|---|---|---|
| CheckMate 025 * | NCT01668784 | Nivolumab | PD-1 | 821 | 23% | 19% | [15,89] |
| CheckMate 214 | NCT02231749 | Nivolumab | PD-1 | 1096 | 39.1% | 47.9% | [21,27,102] |
| Ipilimumab | CTLA-4 | ||||||
| IMmotion 151 | NCT02420821 | Atezolizumab | PD-L1 | 915 | 37% | 40% | [24,30] |
| Bevacizumab | VEGF | ||||||
| JAVELIN Renal 101 | NCT02684006 | Avelumab | PD-L1 | 886 | 52.5% | 71.2% | [23,101,103] |
| Axitinib | RTK | ||||||
| CLEAR | NCT02811861 | Pembrolizumab | PD-1 | 1069 | 71% | 82.4% | [26] |
| Lenvatinib | RTK | ||||||
| Keynote 426 | NCT02853331 | Pembrolizumab | PD-1 | 861 | 60.4% | 66.4% | [25,97,98] |
| Axitinib | RTK | ||||||
| CheckMate 9ER | NCT03141177 | Nivolumab | PD-1 | 651 | 56.6% | 75.3% | [22] |
| Cabozantinib | RTK |
* This study used Everolimus as a control arm. Other studies used Sunitinib as a control arm. Abbreviation: ORR; objective response rate, TRAE; treatment-related adverse event, RTK; receptor tyrosine kinase.